Abstracts Archive - Page 445 of 2607 - ACR Meeting Abstracts

Abstract Number: 1742 • ACR Convergence 2023
Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA
Rachna Talluri¹, Sudeshna Sen², Timothy Wilson³, Adam Savage⁴, Mark Gillespie⁴, Tom Bumol⁴, Marie Feser¹, Jill Norri⁵, Michael Holer¹, kevin Deane¹, Paul Thompson² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Massachusetts Chan Medical School, Worcester, MA, ³Thomas Jefferson University, Philadelphia, PA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Denver, CO
Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
Abstract Number: 1733 • ACR Convergence 2023
Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease
Nozima Aripova¹, Michael Duryee¹, Amy Nelson¹, Carlos Hunter¹, Breanna Butler¹, Bryant England¹, Jill Poole¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a leading cause of mortality in RA with limited treatment options as well as lack of available…
Abstract Number: 2243 • ACR Convergence 2023
Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis Responsiveness: Week 52 Results of an Exploratory Analysis from a Phase 3b Study in Patients with Psoriatic Arthritis
Maria Antonietta D'Agostino¹, Corine Gaillez², Georg Schett³, Maarten Boers⁴, Philippe Carron⁵, Peter Mandl⁶, JAVIER ROSA⁷, Esperanza Naredo⁸, Catherine Bakewell⁹, Weibin Bao¹⁰ and Philip Conaghan¹¹, ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²Novartis Pharma AG, Croissy Sur Seine, France, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁵UZ Gent, Gent, Belgium, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Fundación, Madrid, Spain, ⁹Intermountain Healthcare, Salt Lake City, UT, ¹⁰Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: Enthesitis is a key clinical and imaging hallmark in psoriatic arthritis (PsA). ULTIMATE (NCT02662985) demonstrated responsiveness of ultrasound (US) detected synovitis and enthesitis in…
Abstract Number: 1726 • ACR Convergence 2023
Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis
Melissa Lim¹, Shaghayegh Foroozan², Zoya Qaiyum³, Michael Tang¹, Enoch Yau⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University Health Network/University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis primarily affecting the axial skeleton and commonly coexists with gut and skin inflammation. Currently, patients with…
Abstract Number: 2244 • ACR Convergence 2023
Switching Between Biologics and Targeted Synthetic Therapies Due to Inefficacy in Psoriatic Arthritis
Dalifer Freites Núñez¹, Maria Rodriguez Laguna¹, Cristina Hormigos martín¹, zulema Rosales², Leticia Leon³, Gloria Candelas¹, Daniel Rubio⁴, Jose Otazu¹, Benjamin Fernandez¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ⁴Complutense University, Madrid, Spain
Background/Purpose: Biological and targeted synthetic therapies (ts/bDMARDs) have transformed the management ofPsoriatic arthritis (PsA).However, PsA might experience ts/bDMARD failure, (mainly due to inefficacy), and switching…
Abstract Number: 1740 • ACR Convergence 2023
Exploring Disease-Associated DNA Methylome Alterations in Rheumatoid Arthritis: Potential Diagnostic and Prognostic Biomarkers
Arkaitz Mucientes¹, Martín-Núñez Gracia María², José Lisbona-Montañez³, Patricia Ruiz-Limon⁴, Rocío Redondo-Rodríguez⁵, SARA MANRIQUE⁶, Inmaculada Ureña⁵, Laura Cano-García⁵, Isabel Moreno-Indias¹, Natalia Mena Vazquez⁷ and Antonio Fernandez-Nebro⁸, ¹IBIMA Plataforma BIONAND, Málaga, Spain, ²Universidad de Málaga, Departamento de Medicina y Dermatología, Málaga, Spain, ³Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, ⁴IBIMA Plataforma BIONAND, Cordoba, Spain, ⁵Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁶Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁷IBIMA, Málaga, Spain, ⁸Hospital Regional Universitario de Málaga, Malaga, Spain
Background/Purpose: The etiology of rheumatoid arthritis (RA) is not fully understood. It is accepted that RA results from the interplay of genetic and environmental factors.…
Abstract Number: 1736 • ACR Convergence 2023
The Effect of Resolvin E1 and Resolvin D1 Specialised Pro-resolving Mediators on the Inhibition of Osteoclastogenesis
Patricia Riedlova¹, Kieran Woolcock², Cecilia Ansalone² and Carl Goodyear², ¹University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Osteoclasts (OCs) are multinucleated bone-resorbing cells playing a key role in rheumatoid arthritis (RA). Under physiological conditions, OCs are in balance with bone-forming osteoblasts,…
Abstract Number: 2240 • ACR Convergence 2023
Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
Aisha Vadhariya¹, Sarah Ross¹, Brenna Brady², Helen Varker², Anh Thu Tran² and Jessica A Walsh³, ¹Eli Lilly and Company, Indianapolis, IN, ²Merative, Cambridge, MA, ³Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: The treatment paradigm for psoriatic arthritis (PsA) has changed over the last two decades, with increasing numbers of therapy options that target a variety…
Abstract Number: 1717 • ACR Convergence 2023
Endothelial Cell Sphingosine 1-Phophate Receptor 1 Restrains VE-cadherin Cleavage and Attenuates Experimental Inflammatory Arthritis
Nathalie Burg¹, Miles Tran², Kevin Wei³, Carl Blobel¹ and Jane Salmon¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In rheumatoid arthritis, inflammatory mediators extravasate from blood into joints via gaps between endothelial cells (EC), but the contribution of ECs to inflammatory arthritis…
Abstract Number: 1622 • ACR Convergence 2023
Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality
Matthew Sherman¹, Payam Noroozi Farhad², Katherine Pak³, Iago Pinal-Fernandez³, Kakali Sarkar², Megan Neely⁴, Ira Targoff⁵, Frederick Miller⁶, Andrew Mammen⁷ and Lisa Rider⁸, ¹NIAMS/NIH, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, ⁵Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶NIH, NIEHS, Chapel Hill, NC, ⁷NIH, Bethesda, MD, ⁸NIEHS, NIH, Bethesda, MD
Background/Purpose: Myositis-associated autoantibodies (MAAs), such as anti-Ro52 autoantibodies (Abs), have been found to be associated with interstitial lung disease (ILD) and worse prognosis in the…
Abstract Number: 1737 • ACR Convergence 2023
ACPA, Anti-CarP and AAPA Can Be Detected in Saliva, but Not in Feces of Seropositive Rheumatoid Arthritis Patients – Support for Mucosal Involvement in Specific Locations in RA
Veerle Derksen¹, Klara Martinsson², René Toes¹, Daniel Sjöberg³, Thomas Huizinga¹, Alf Kastbom⁴, Anna Svärd³ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Linköping University, Linköping, Sweden, ³Centre for Clinical Research Dalarna, Uppsala, Sweden, ⁴Linköping University, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) patients harbor antibodies against several post-translational modifications (AMPA), for example anti-citrullinated protein antibodies (ACPA), anti-carbamylated antibodies (anti-CarP) and anti-acetylated protein antibodies…
Abstract Number: 1625 • ACR Convergence 2023
Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning
santiago arciniegas¹, Matthias W. Wagner², Logi Vidarsson², Birgit Ertl-Wagner², Tala El Tal³, Asha Jeyanathan², Lawrence Ng², Linda Hiraki², Deborah Levy², George M. Ibrahim² and Andrea Knight², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Childhood-onset SLE (cSLE) is characterised by a higher frequency of nervous system involvement, known…
Abstract Number: 1626 • ACR Convergence 2023
Clinical Presentation, Disease Course and 12-month Outcomes in Childhood Polyarteritis Nodosa: A PedVas Study
Shamma Alzaabi¹, Else Bosman¹, David Cabral², Kimberly Morishita¹ and PedVas Investigators Network³, ¹Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, BC, Canada, ²BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ³Pediatric Rheumatology, British Columbia Children Hospital, Vancouver, Canada, Vancouver, BC, Canada
Background/Purpose: Childhood polyarteritis nodosa (PAN) is a systemic vasculitis with necrotizing inflammation that typically affects small and medium-sized arteries. The clinical presentation is variable; it…
Abstract Number: 1638 • ACR Convergence 2023
CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Having High Disease Activity or High Symptom Burden
Tuyet-Hang Pham¹, Michael A. Smith¹, Nannette Mittereder¹, William A. Rees², Ilias Alevizos², E. William St. Clair³ and Claire Emson¹, ¹Horizon Therapeutics plc, Rockville, MD, ²Horizon Therapeutics, Rockville, MD, ³Duke University Medical Center, Durham, NC
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
Abstract Number: 1217 • ACR Convergence 2023
Sex Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey
Lihi Eder¹, Pascal Richette², Laura Coates³, Valderilio Feijó Azevedo⁴, Joseph C. Cappelleri⁵, Megan Hoang⁶, Jade Moser⁷ and Meriem Kessouri⁸, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Lariboisière Hospital, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc., New York, NY, ⁷The Harris Poll, Rochester, NY, ⁸Pfizer Inc., Paris, France
Background/Purpose: Women with PsA have more severe disease activity and lower health-related quality of life vs men.1 This post hoc analysis assessed sex differences in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].